Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Performer

2576.8500 38.60 (1.52%)

NSE Mar 17, 2025 15:31 PM

26.06% Fall from 52W High

Volume: 93,024

Ajanta Pharma Ltd.

03 May 2024

2576.85

1.52%

Ajanta Pharma (BUY): Strong margins; growth momentum to continue

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Strong quarter with EBITDA/PAT beat of 8% each, led by reduction in API prices, logistics costs and reduced intensity of US price erosion

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.